Brief: CASI Pharmaceuticals Announces Clinical Hold Of CID-103

CASI Pharmaceuticals

26/12/2024 15:41

Dec 26 (Reuters) - CASI Pharmaceuticals Inc  CASI.O :
    * CASI PHARMACEUTICALS INC: ANNOUNCES CLINICAL HOLD OF
CID-103 FOR
ANTIBODY MEDIATED REJECTION (AMR) OF KIDNEY TRANSPLANT
    * CASI PHARMACEUTICALS: FDA PLANS TO PROVIDE FORMAL WRITTEN
RESPONSE BEFORE STATUTORY DEADLINE
    * CASI PHARMACEUTICALS: CID-103 IND APPLICATION SUPPORTING
PHASE
1-2 STUDY OF CID-103 IN ADULTS WITH CHRONIC IMMUNE
THROMBOCYTOPENIA REMAINS OPEN
    * CASI PHARMACEUTICALS: ACCRUAL TO PHASE 1-2 STUDY OF
CID-103
EXPECTED TO COMMENCE IN Q1 2025


Further company coverage:  CASI.O 

 ((Reuters.Briefs@thomsonreuters.com;))